Cargando…
Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England
BACKGROUND: Hyperadrenocorticism is an endocrine disease routinely encountered within primary care practice; however, few studies evaluating survival beyond diagnosis have studied this population. METHODS: This retrospective cohort study analysed the electronic patient records of 219 cases of hypera...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146928/ https://www.ncbi.nlm.nih.gov/pubmed/31542726 http://dx.doi.org/10.1136/vr.105159 |
_version_ | 1783520314769014784 |
---|---|
author | Schofield, Imogen Brodbelt, David C Wilson, Anna R L Niessen, Stijn Church, David O'Neill, Dan |
author_facet | Schofield, Imogen Brodbelt, David C Wilson, Anna R L Niessen, Stijn Church, David O'Neill, Dan |
author_sort | Schofield, Imogen |
collection | PubMed |
description | BACKGROUND: Hyperadrenocorticism is an endocrine disease routinely encountered within primary care practice; however, few studies evaluating survival beyond diagnosis have studied this population. METHODS: This retrospective cohort study analysed the electronic patient records of 219 cases of hyperadrenocorticism from a sample of dogs attending primary care practices in England. Kaplan-Meier plots examined the cumulative survival and Cox proportional hazard regression modelling identified factors associated with the hazard of all-cause mortality. RESULTS: In the analysis, 179/219 (81.7 per cent) hyperadrenocorticism cases died during the study period with a median survival time from first diagnosis of 510 days (95% CI 412 to 618 days). Trilostane was used in 94.1 per cent of cases and differentiation between pituitary-dependent and adrenal-dependent disease was made in 20.1 per cent of cases. In the multivariable analysis, dogs weighing greater than or equal to 15 kg (HR 1.51, 95% CI 1.06 to 2.15, P=0.023) and those diagnosed greater than or equal to 13 years of age (HR 3.74, 95% CI 2.29 to 6.09, P<0.001) had increased hazards of all-cause mortality. Dogs that had their initial trilostane dose increased had a favourable prognosis (HR 0.49, 95% CI 0.32 to 0.76, P=0.015). CONCLUSION: This study shows that survival from diagnosis of hyperadrenocorticism appears fair for many dogs and provides primary care practitioners with relatable benchmark prognostic figures. |
format | Online Article Text |
id | pubmed-7146928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-71469282020-04-15 Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England Schofield, Imogen Brodbelt, David C Wilson, Anna R L Niessen, Stijn Church, David O'Neill, Dan Vet Rec Paper BACKGROUND: Hyperadrenocorticism is an endocrine disease routinely encountered within primary care practice; however, few studies evaluating survival beyond diagnosis have studied this population. METHODS: This retrospective cohort study analysed the electronic patient records of 219 cases of hyperadrenocorticism from a sample of dogs attending primary care practices in England. Kaplan-Meier plots examined the cumulative survival and Cox proportional hazard regression modelling identified factors associated with the hazard of all-cause mortality. RESULTS: In the analysis, 179/219 (81.7 per cent) hyperadrenocorticism cases died during the study period with a median survival time from first diagnosis of 510 days (95% CI 412 to 618 days). Trilostane was used in 94.1 per cent of cases and differentiation between pituitary-dependent and adrenal-dependent disease was made in 20.1 per cent of cases. In the multivariable analysis, dogs weighing greater than or equal to 15 kg (HR 1.51, 95% CI 1.06 to 2.15, P=0.023) and those diagnosed greater than or equal to 13 years of age (HR 3.74, 95% CI 2.29 to 6.09, P<0.001) had increased hazards of all-cause mortality. Dogs that had their initial trilostane dose increased had a favourable prognosis (HR 0.49, 95% CI 0.32 to 0.76, P=0.015). CONCLUSION: This study shows that survival from diagnosis of hyperadrenocorticism appears fair for many dogs and provides primary care practitioners with relatable benchmark prognostic figures. BMJ Publishing Group 2020-03-21 2019-09-20 /pmc/articles/PMC7146928/ /pubmed/31542726 http://dx.doi.org/10.1136/vr.105159 Text en © British Veterinary Association 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Paper Schofield, Imogen Brodbelt, David C Wilson, Anna R L Niessen, Stijn Church, David O'Neill, Dan Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England |
title | Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England |
title_full | Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England |
title_fullStr | Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England |
title_full_unstemmed | Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England |
title_short | Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England |
title_sort | survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in england |
topic | Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146928/ https://www.ncbi.nlm.nih.gov/pubmed/31542726 http://dx.doi.org/10.1136/vr.105159 |
work_keys_str_mv | AT schofieldimogen survivalanalysisof219dogswithhyperadrenocorticismattendingprimarycarepracticeinengland AT brodbeltdavidc survivalanalysisof219dogswithhyperadrenocorticismattendingprimarycarepracticeinengland AT wilsonannarl survivalanalysisof219dogswithhyperadrenocorticismattendingprimarycarepracticeinengland AT niessenstijn survivalanalysisof219dogswithhyperadrenocorticismattendingprimarycarepracticeinengland AT churchdavid survivalanalysisof219dogswithhyperadrenocorticismattendingprimarycarepracticeinengland AT oneilldan survivalanalysisof219dogswithhyperadrenocorticismattendingprimarycarepracticeinengland |